COMPANY ANNOUNCES STRATEGIC FOCUS
March 23 2005 - 11:01AM
UK Regulatory
23rd March 2005
Tepnel Life Sciences PLC (`Tepnel' or `the Company')
COMPANY ANNOUNCES STRATEGIC FOCUS ON REAGENT
PRODUCTS AND SERVICES
Withdrawal from lab equipment business
Manchester, U.K. The Company (AIM: TED) has announced that following a
strategic decision by the board to focus on research products & services and
molecular diagnostics, it has withdrawn from the specialist DNA-purification
instrument business.
Tepnel has since 31st December 2004 ceased the research, development, sales and
marketing activities associated with Nucleopure and Nucleoplex instrument
systems. The company has provided at year-end a total of �547,000, comprising �
506,000 for write down of stocks and �41,000 in redundancy costs for people
employed directly or indirectly on these projects. Annualised payroll savings
associated with the cessation of this activity are estimated at �250,000.
The benefits of this decision are expected to contribute positively to
financial results for the year ended 31st December 2005.
For Further Information:
Tepnel Life Sciences plc
Ben Matzilevich, CEO
Gron Ffoulkes-Davies, Finance Director
0161 946 2200
Seymour Pierce
Mark Percy, Corporate Finance
0207 107 8000
De Facto Communications
Richard Anderson
020 7940 1000
Notes to Editors
About Tepnel Life Sciences plc
Tepnel is a UK-based international life sciences company focused on molecular
diagnostics and research products and services including DNA purification kits
and reagents, scientific services for nucleic acid purification, drug analysis,
genotyping and genetically modified foods. Tepnel was founded in 1992 to
exploit DNA technology generated at UMIST (University of Manchester Institute
of Science and Technology) and is quoted on the AIM segment of the London Stock
Exchange (AIM: TED). More information on Tepnel can be found at www.tepnel.com.
END
Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024